ROSE 试验中急性呼吸窘迫综合征的分子表型:结局及基线与纵向基因表达差异
在 ROSE 试验(中重度 ARDS 患者接受顺阿曲库铵治疗)中开展潜在类别分析,识别出低炎症型(60.4%)与高炎症型(39.6%)两种分子表型。高炎症型第 90 天死亡率更高(30.3% vs. 61.6%,P < 0.0001),但表型与随机分组间无治疗交互作用。对 134 例患者全血 RNA 测序显示两表型在基线与第 2 天基因表达及纵向变化模式不同,且受存活状态影响。
要点
- ROSE 试验再现低炎症与高炎症两表型,高炎症型占比 39.6%。
- 高炎症型第 90 天死亡率高于低炎症型(61.6% vs. 30.3%)。
- 表型与神经肌肉阻滞治疗间未见死亡率交互作用。
核心结论
- 高炎症型与低炎症型 ARDS 具有不同的临床、蛋白及动态转录特征,支持分子表型用于推进 ARDS 精准诊疗。
研究设计与样本
- 对 ROSE 试验(中重度 ARDS 顺阿曲库铵研究)行潜在类别分析,使用入组前临床与蛋白生物标志物;134 例患者亚组行全血 RNA 测序(入组时及第 2 天)并作差异基因表达与通路分析。
主要发现
- 识别低炎症型 60.4% 与高炎症型 39.6%,生物学与临床特征与既往研究相似。
- 高炎症型第 90 天死亡率 61.6%,低炎症型 30.3%(P < 0.0001)。
- 表型与随机分组间死亡率无治疗交互作用。
- 高炎症型第 0 天富集固有免疫应答、组织重塑与锌代谢相关基因,第 2 天富集胶原合成与中性粒细胞脱颗粒相关基因。
- 基因表达纵向变化模式因存活状态而异;多数高表达基因与对应血浆蛋白丰度相关,但潜在类别分析中的分类定义血浆蛋白与其基因表达无相关。
关键数值与推荐
- 高炎症型与低炎症型第 90 天死亡率分别为 61.6% 与 30.3%(P < 0.0001)。
临床怎么用
- 可依据临床与蛋白生物标志物识别的分子表型对 ARDS 患者分层,高炎症型预后更差需更密切关注;表型尚未能指导神经肌肉阻滞剂的选择。
局限性
- 基因表达分析仅限 134 例患者亚组;表型与治疗无交互作用,尚不能据此改变治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Two molecular phenotypes have been identified in acute respiratory distress syndrome (ARDS). In the ROSE (Reevaluation of Systemic Early Neuromuscular Blockade) trial of cisatracurium in moderate to severe ARDS, we addressed three unanswered questions: 1) Do the same phenotypes emerge in a more severe ARDS cohort with earlier recruitment; 2) Do phenotypes respond differently to neuromuscular blockade? and 3) What biological pathways most differentiate inflammatory phenotypes?Methods: We performed latent class analysis in ROSE using preenrollment clinical and protein biomarkers. In a subset of patients (n = 134), we sequenced whole-blood RNA using enrollment and Day 2 samples and performed differential gene expression and pathway analyses. Informed by the differential gene expression analysis, we measured additional plasma proteins and evaluated their abundance relative to gene expression amounts.Measurements and Main Results: In ROSE, we identified the hypoinflammatory (60.4%) and hyperinflammatory (39.6%) phenotypes with similar biological and clinical characteristics as prior studies, including higher mortality at Day 90 for the hyperinflammatory phenotype (30.3% vs. 61.6%; P < 0.0001). We observed no treatment interaction between the phenotypes and randomized groups for mortality. The hyperinflammatory phenotype was enriched for genes associated with innate immune response, tissue remodeling, and zinc metabolism at Day 0 and collagen synthesis and neutrophil degranulation at Day 2. Longitudinal changes in gene expression patterns differed dependent on survivorship. For most highly expressed genes, we observed correlations with their corresponding plasma proteins' abundance. However, for the class-defining plasma proteins in the latent class analysis, no correlation was observed with their corresponding genes' expression.Conclusions: The hyperinflammatory and hypoinflammatory phenotypes have different clinical, protein, and dynamic transcriptional characteristics. These findings support the clinical and biological potential of molecular phenotypes to advance precision care in ARDS.
引用
- Sinha P, Neyton L, Sarma A, et al. Molecular Phenotypes of Acute Respiratory Distress Syndrome in the ROSE Trial Have Differential Outcomes and Gene Expression Patterns That Differ at Baseline and Longitudinally over Time. Am J Respir Crit Care Med. 2024. PMID: 38345571. doi:10.1164/rccm.202308-1490OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。